Adam Craig
Chief Executive Officer chez CTI BIOPHARMA CORP.
Profil
Adam R.
Craig is currently the President, Chief Executive & Medical Officer at CTI BioPharma Corp.
He is also a Member at The Royal College of Physicians and The Royal College of Paediatrics & Child Health.
Previously, he served as the Medical Director & Vice President at ArQule, Inc., Senior Director at ILEX Oncology, Inc., and Chief Medical Officer & Executive VP-Development at Sunesis Pharmaceuticals, Inc. from 2013 to 2016.
He was also the Founding Chief Medical Officer & Vice President at Innovive Pharmaceuticals, Inc. in 2007, Chief Medical Officer & Senior Vice President at ChemGenex Pharmaceuticals Pty Ltd.
from 2009 to 2011, and Chief Medical Officer & Senior Vice President at ChemGenex Pharmaceuticals, Inc. from 2008 to 2012.
Dr. Craig holds a doctorate degree from the University of Leeds and Charing Cross Hospital Medical School, as well as an MBA from The Open University Business School.
Postes actifs de Adam Craig
| Sociétés | Poste | Début |
|---|---|---|
| CTI BIOPHARMA CORP. | Chief Executive Officer | 20/03/2017 |
| The Royal College of Physicians | Corporate Officer/Principal | 06/01/2011 |
| The Royal College of Paediatrics & Child Health | Corporate Officer/Principal | - |
Anciens postes connus de Adam Craig
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2016 |
ChemGenex Pharmaceuticals, Inc.
 ChemGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
ChemGenex Pharmaceuticals Pty Ltd.
 ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Chief Tech/Sci/R&D Officer | 01/12/2011 |
Innovive Pharmaceuticals, Inc.
 Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | Chief Tech/Sci/R&D Officer | 30/09/2007 |
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Director/Board Member | - |
Formation de Adam Craig
| University of Leeds | Doctorate Degree |
| The Open University Business School | Masters Business Admin |
| Charing Cross Hospital Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | Health Technology |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Health Technology |
ChemGenex Pharmaceuticals, Inc.
ChemGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA. | Health Technology |
